1. 个人简介：

黄维娟，副教授，博士生导师。2019年于暨南大学获博士学位，2020年作为第四层次高层次引进人才（“青蓝学者”）入职暨南大学药学院。主要研究方向为肿瘤药理学，长期围绕“肿瘤耐药新机制发现及药物靶点鉴定”这一核心科学问题开展系统性研究。以第一作者或通讯作者在Lancet Oncol，Mol Cancer，J Exp Clin Canc Res，Int J Surg，Oncogene, Leukemia，Sci. China Life Sci，Int J Biol Macromol等国际权威期刊发表研究论文30余篇。主持国家级及省部级科研项目共5项，包括国家自然科学基金面上项目、国家自然科学基金青年科学基金项目、广东省自然科学基金面上项目、中国博士后科学基金面上项目等。教学方面，主讲本科生及研究生课程《中药生物技术》《中药学导论》《中药生物技术进展》及《中药生物技术前沿与进展》；参与研究生《高等药理学》及《高等药理学进展》的课程教学。参编全英文教材2部，申请国家发明专利2项。

2. 研究方向：

（1）中药抗肿瘤药理学；

（2）肿瘤耐药分子标签；

（3）临床医学转化。

 3. 主持的科研项目：

（1）circBPTF_069编码新蛋白BPTF-667aa增强染色质可及性诱导T-LBL/ALL化疗耐药的机制研究（82574486）国家自然科学基金面上项目，2026年1月-2029年12月；

（2）基于长链非编码RNA LINC00663调控miR-194-3P表达探究晚期非小细胞肺癌耐药的分子机制及青蒿素B的干预机理（82003774），国家自然科学基金青年基金，2021年1月-2023年12月；

（3）青蒿素B靶向环状RNA Circ-HIPK3调控晚期非小细胞肺癌耐药的机理研究（2024A1515010185）,广东省自然科学基金委, 面上项目 2024-01-2026-12；

（4）青蒿素B靶向LINC00663调控晚期非小细胞肺癌耐药的机理研究（2020M673091），中国博士后科学基金第67批面上资助，2020年6月-2022年3月；

（5）环状RNA Circ-UNP155通过调控穹隆体RNA vtRNA1-3的表达影响T淋巴母细胞淋巴瘤/白血病复发耐药的机制研究，广东省自然科学基金面上项目，2023年1月-2025年12月。

4. 代表性论文

(1) Guo SB^#, Meng Y^#, Lin L^#, Zhou Z^#Z, Li HL, Tian XP^*, Huang WJ^*. Artificial intelligence alphafold model for molecular biology and drug discovery: a machine-learning-driven informatics investigation. Molecular Cancer.2024 Oct 5;23(1):223.（1区TOP，IF：33.8，最后通讯）

(2) Rong-Hui Chen^#, Mei Li^#, Zhen-Zhong Zhou^#, Xiao-Jie Fang^#, Yong Zhu, Yuan Zhang, Xu Liu, Hai-Long Li, Jing Feng, Li-Yan Song, Rong-Min Yu, Tian-Xiao Gao^*,  Xiao-Peng Tian^*, Wei-Juan Huang^*. BPTF-665aa mediate chromatin remodeling drives chemoresistance in T-LBL/ALL. Journal of Experimental & Clinical Cancer Research.2025;44:302.（中科院1区，IF：12.658，最后通讯）

(3) Wei-Juan Huang^#, Song-Bin Guo^#, Hui Shi^#, Xin-Ling Li^#, Yong Zhu, Mei Li, Li-Yan Song, Rong-Min Yu^*, Qing-Qing Cai^*, Xiao-Peng Tian^*. The β-catenin-LINC00183-miR-371b-5p- Smad2/LEF1 axis promotes adult T-cell lymphoblastic lymphoma progression and chemoresistance.Journal of Experimental & Clinical Cancer Research. 2023;42:105.（中科院1区，IF：12.658，第一作者排第一）

(4) HuangWei-Juan^#,Tian Xiao-Peng^#,Bi Si-Xue^#,Zhang Si-Rui^#, HeTing-Sha, Song Li-Yan, Yun Jing-Ping, Zhou Zhong-Guo, Yu Rong-Min*,LiMei*. Theβ-catenin/TCF-4-LINC01278-miR-1258-Smad2/3 axis promotes hepatocellular carcinoma metastasis.Oncogene, 2020 Jun;39(23):4538-4550.（中科院1区，IF: 7.971 ，第一作者排第一）

(5) Huang Wei-juan^#, Wang Yan-qing^#, He Ting-sha^#, Zhu Jian-hua, Li Jian-huan, Zhang Si-rui, Zhu Yong , Xu Ya-fang, Xu Lv, Wang Hao-ran, Yu Rong-min^*and Song Li-yan^*. Arteannuin B Enhances the Effectiveness of Cisplatin in Non-Small Cell Lung Cancer by Regulating Connexin 43 and MAPK Pathway. The American Journal of Chinese Medicine. 2022; 31:1-30.（中科院2区，IF: 6.009, 第一作者排第一）

(6) Song-Bin Guo^#; Xiu-Yu Cai^#; Yuan Meng; Wei-Juan Huang^*; Xiao-Peng Tian^*. AI model using clinical images for genomic prediction and tailored treatment in patients with cancer. The Lancet Oncology, 2025, 26(3).（1区TOP，IF：41.6，共同通讯）

(7) Ting-Sha He^#, Rong-Hui Chen^#, Jing Feng^#, Qiang Zhang, Xin-Ling Li, | Jia-Hui Han, Tian-Ze Chen3, Rong-Min Yu, Li-Yan Song^*, Wei-Juan Huang^*. Arteannuin B Inhibits NSCLC Cells via Regulating miR-194-3p/CLDN2 Axis. Cancer Medicine. 2026;15:e71796. （3区，IF：3.5，最后通讯）

(8) Zhou ZZ^#, Lu JC^#, Guo SB^#, Tian XP^#, Li HL, Zhou H^*, Huang WJ^*. A Mitochondria-Related Signature in Diffuse Large B-Cell Lymphoma: Prognosis, Immune and Therapeutic Features. Cancer Medicine. 2025 Jan;14(2):e70602. （3区，IF：3.5，最后通讯）

(9) Hailong Li^#, Hui Zhou^#, Yi-Yang Zhang^#, Jin-Ting Lai^#, Zhen-Zhong Zhou, Jing-Yi Huang , Song-Bin Guo , Yu Wang^*, Wei-Juan Huang^*,Xiao-Peng Tian^*. ESIRA, a Novel Framework Integrating Efficacy and Safety for Evaluating First-Line Treatments in Advanced Hepatocellular Carcinoma. SCIENCE CHINA Life Sciences. 2025; https://doi.org/10.1007/s11427-025-3093-8（中科院1区，IF：9.5，Top期刊，共同通讯）

(10) Song-Bin Guo^#, Ying Shen^#, Yuan Meng^#, Zhen-Zhong Zhou, Hai-Long Li, Xiu-Yu Ca^*i, Wei-Juan Huang^*, Xiao-Peng Tian^*. Surge in large language models exacerbates global regional healthcare inequalities. Journal of Translational Medicine. 2025;23:706.(2区，IF：7.4，共同通讯)

(11) Guo SB^#, Hu LS^#, Huang WJ^#, Zhou ZZ, Luo HY, Tian XP^*. Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, and large-sample informatics study. International Journal of Surgery. 2024 Aug 1;110(8):4660-4671.（1区，IF：12.5，共同第一排第三）

(12) Jiang LJ^#, Guo SB^#, Zhou ZH^#, Li ZY^#, Zhou FJ, Yu CP, Li M,Huang WJ^*, Liu ZW^*, Tian XP^*. Snai2-mediated upregulation of NADSYN1 promotes bladder cancer progression by interacting with PHB. Clinical and Translation Medicine.2024 Jan;14(1):e1555.（1区，IF：7.9，共同通讯）；

(13) Guo SB^#, Feng XZ^#, Huang WJ^#, Zhou ZZ, Tian XP^*. Global research hotspots, development trends and prospect discoveries of phase separation in cancer: a decade-long informatics investigation. Biomarker  research. 2024 Apr 16;12(1):39.（1区，IF:9.5，共同第一排第三）

(14) Man Zhang^#, Xiaozheng Ou^#, Hui Shi, Weijuan Huang*, Liyan Song, Jianhua Zhu*, Rongmin Yu*. Isolation, structures and biological activities of medicinal glycoproteins from natural resources: A review. International Journal of Biological Macromolecules, 2023; 244:125406. （中科院1区，IF: 8.025, 共同通讯）

(15) Luo Yuan yuan^#, Li Chun-lei^#, He Ting-sha, Huang Wei-juan^#, Wang Yu-rong, Yu Dong-Bo, Ma Min^#, Yu Rong-min, Zhu Jian-hua^*, Song Li-yan^*. A highly branched α-d-glucan facilitates antitumor immunity by reducing cancer cell CXCL5 expression. International Journal of Biological Macromolecules, 2022; 209:166-179. （中科院1区，IF: 8.025，第一作者排第四）

(16) Song-Bin Guo^#, Dan-Qi Pan^#, Ning Su^#, Man-Qian Huang^#, Zhen-Zhong Zhou, Wei-Juan Huang*, Xiao-Peng Tian*. Comprehensive scientometrics and visualization study profiles lymphoma metabolism and identifies its significant research signatures. Frontiers in Endocrinology.2023,14:1266721. (中科院2区，IF: 5.2, 共同通讯)

(17) Jiang Li-Juan^#,Guo Song-Bin^#, Huang Zhong-Ying, Cao Chang-Hong, Jin Xiao-Han, Li Xin-Ling, Huang Wei-Juan^*, Tian Xiao-Peng^*, PHB promotes bladder cancer cell epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway.Pathology-Research and Practice. 2023 (247) 154536. (中科院四区，IF:2.8, 共同通讯)

(18) Song-Bin Guo, Sheng Du, Ke-Yu Cai, Han-Jia Cai, Wei-Juan Huang g, Xiao-Peng Tian. A scientometrics and visualization analysis of oxidative stress modulator Nrf2 in cancer profiles its characteristics and reveals its association with immune response. Heliyon. 2023,(9):e17075.(中科院四区，IF:4.0, 共同通讯)

5. 联系方式

wjhuang@jnu.edu.cn;